Kevin Grogan
Managing Editor, Europe
Covering all aspects of the pharma industry and across all therapeutic areas, Kevin has interviewed pretty much all the leading figures in the sector. A regular attendee at financial and medical conferences (and moderating at some), he has also appeared on BBC television and radio, ITV and Channel 4 to discuss the industry. Fluent in Spanish, he previously worked as a journalist on rock/pop music publications, was chief sub editor at Catholic newspaper The Universe and contributed articles to the likes of The Independent and the Manchester Evening News on football.
Latest From Kevin Grogan
Take Five: Ipsen Bags Rights To Day One Brain Cancer Drug
The Paris-based group has inked five external deals already this year, this time paying $111m to get access internationally to Day One Biopharmaceuticals' Ojemda for refractory pediatric low-grade glioma.
Farxiga Flying Off The Shelf At AstraZeneca
The UK major has raised its full-year sales and earnings forecast on strong demand in the second quarter for its cancer, rare disease and cardiovascular medicines.
AstraZeneca Cultivates Oncology Pipeline With Pinetree Pact
Deal Snapshot: Degrading rather than inhibiting a target protein has emerged as one of the most promising approaches in drug discovery and AstraZeneca is paying handsomely to advance its presence in the space.
Almirall Pleased With Promising Start For Ebglyss
The Barcelona-headquartered group’s Lilly-partnered atopic dermatitis drug is enjoying a decent launch in Germany and reimbursement has just been secured in the UK.
Narasimhan Playing The Long Game At Novartis
The head of the Basel-headquartered giant is no fan of bidding wars when it comes to dealmaking. "If we are outbid and it’s not within our envelope, we just walk away and we’re okay with that.”
Cosentyx Delivers Again For Novartis With Hidradenitis Suppurativa Launch
Two older drugs – Cosentyx and Entresto – continue to drive growth at the Swiss giant, while Leqvio is finally making its mark on the sales front.